V

    Vyne Therapeutics Inc (VYNE)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $28.56
    +3.11 (+12.22%)

    Market Cap: $19.07M

    Last updated: Jul 27, 2026 at 5:00 PM ET

    Earnings

    Performance (10Y)

    Beat Rate
    61%(20/33)
    Avg Surprise
    +1.76%
    Streak
    1 Q
    PeriodReportedEst.SurpriseB/MYoY
    Jun 26
    Reported Aug 13
    		$N/A$-0.18N/ABeat-
    Mar 26
    Reported May 15
    		$-0.08N/AN/ABeat+99.2%
    Dec 25
    Reported Mar 12
    		$-5.50N/A+52.17%Beat-1849.0%
    Sep 25
    Reported Nov 6
    		$-8.50$-6.50-30.77%Miss+41.4%
    Jun 25
    Reported Aug 14
    		$-6.50$-11.17+41.81%Beat+40.9%
    Mar 25
    Reported May 8
    		$-10.00$-14.50+31.03%Beat-6566.7%
    Dec 24
    Reported Mar 6
    		$-0.28$-0.30+6.96%Beat+97.2%
    Sep 24
    Reported Nov 7
    		$-14.50$-11.75-23.40%Miss+85.6%
    Jun 24
    Reported Aug 14
    		$-11.00$-9.50-15.79%Miss+92.9%
    Mar 24
    Reported May 9
    		$-0.15$-0.24+37.50%Beat+99.8%
    Dec 23
    Reported Feb 29
    		$-10.00N/A+60.00%Beat-200.3%
    Sep 23
    Reported Nov 13
    		$-100.50$-38.00-164.47%Miss+20.2%
    Jun 23
    Reported Aug 14
    		$-154.50$-129.00-19.77%Miss-32.1%
    Mar 23
    Reported May 11
    		$-87.00$-130.50+33.33%Beat-3352.4%
    Dec 22
    Reported Mar 9
    		$-3.33$-3.24-2.78%Miss+98.1%
    Sep 22
    Reported Nov 10
    		$-126.00$-180.00+30.00%Beat+61.1%
    Jun 22
    Reported Aug 12
    		$-117.00$-135.00+13.33%Beat+62.9%
    Mar 22
    Reported May 12
    		$-2.52$-2.97+15.15%Beat+99.2%
    Dec 21
    Reported Mar 17
    		$-180.00$-231.00+22.08%Beat-1718.2%
    Sep 21
    Reported Nov 10
    		$-324.00$-290.25-11.63%Miss+40.0%
    Jun 21
    Reported Aug 12
    		$-315.54$-318.60+0.96%Beat+36.5%
    Mar 21
    Reported May 6
    		$-333.00$-358.20+7.04%Beat+85.3%
    Dec 20
    Reported Mar 4
    		$-9.90$-9.60-3.13%Miss+84.6%
    Sep 20
    Reported Nov 5
    		$-540.00$-540.00+0.00%Beat-971.4%
    Jun 20
    Reported Aug 6
    		$-496.80$-747.00+33.49%Beat-900.0%
    Mar 20
    Reported May 11
    		$-2264.04$-2232.00-1.44%Miss-3782.1%
    Dec 19
    Reported Mar 3
    		$-64.08$-59.47-7.75%Miss-17.1%
    Sep 19
    Reported Oct 31
    		$-50.40$-55.56+9.29%Beat-25.0%
    Jun 19
    Reported Aug 1
    		$-49.68$-60.62+18.05%Beat-91.7%
    Mar 19
    Reported May 2
    		$-58.32$-58.18-0.24%Miss-12.5%
    Dec 18
    Reported Feb 27
    		$-54.72$-58.32+6.17%Beat+57.8%
    Sep 18
    Reported Nov 7
    		$-40.32$-63.79+36.79%Beat-7507.5%
    Jun 18
    Reported Aug 1
    		$-25.92N/A+54.43%Beat-2300.0%
    Mar 18
    Reported May 9
    		$-51.84$-47.88-8.27%Miss-
    Dec 17
    Reported Jan 26
    		$-129.60$-49.44-162.14%Miss-
    Sep 17
    Reported Oct 30
    		$-0.53$0.00N/AMiss-
    Mar 17
    Reported Jun 29
    		$-1.08$0.00N/AMiss-

    Dividends

    Dividend Metrics

    Yield0.00%
    Annual/Share$0.00
    Pay MonthsJul

    Key Metrics

    Valuation
    P/E RatioN/AEV/EBITDA1.84x
    Price/FCFN/AFCF YieldN/A
    Profitability
    Profit Margin0.00%Operating Margin-4437.00%
    ROE-63.20%ROICN/A
    Financial Health
    Debt/EquityN/AInterest CoverageN/A
    Current RatioN/AQuick RatioN/A
    Trading Statistics
    Beta2.01Avg VolumeN/A
    52-Week High$46.9552-Week Low$0.00

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$5.76
    SMA 20$3.07
    SMA 50$1.45
    SMA 200$0.58
    EMA 10$9.28
    EMA 20$5.26
    EMA 50$2.44
    EMA 200$0.92

    MACD

    Line: 3.81Signal: 1.10Hist: 2.71

    ADX

    ADX: 36.9+DI: 298.8-DI: 4.3

    Aroon & PSAR

    Aroon Up100.0
    Aroon Down96.0
    PSAR$0.47

    Bollinger Bands

    Upper Band$19.47
    Lower Band$-13.34
    %B Position106967%(Upper)
    Band Width1.28

    RSI (14-Day)

    Overbought
    99.9

    Momentum Oscillators

    Stoch %K1798.9
    Stoch %D1172.2
    Williams %RN/A
    ROC (10d)7673.5%
    Momentum28.19
    CCI (20d)527.1
    MFI (14d)81.2

    Volatility Measures

    ATR (14d)$0.67(2.4%)
    StdDev (20d)8.20
    Hist Vol17153.6%(High)

    Volume Flow

    VWAP$26.83
    OBV243.1M
    AD Line-3.3B
    CMF (20d)36.588

    Volume Metrics

    Avg Vol (20d)2.0M
    Vol Ratio0.0x(Low)
    VWMA (20d)$2.33

    Pivot Points

    R3$17.25
    R2$8.90
    R1$17.18
    Pivot Point$8.82
    S1$17.10
    S2$8.74
    S3$17.02

    Advanced Oscillators

    TSI99.16
    Ultimate Osc357.6
    KST12716.46

    Financial Data

    QuarterMar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023Jun 2023
    Total Revenue$86,000$130,000$169,000$69,000$202,000$84,000$121,000$198,000$98,000$76,000$114,000$135,000
    Cost of Revenue$0$5,000$12,000$0$0$4,000$0$0$0N/A$0$0
    Gross Profit$86,000$130,000$169,000$69,000$202,000$84,000$121,000$198,000$98,000$76,000$114,000$135,000
    Operating Expenses$3.90M$5.35M$7.96M$7.61M$9.40M$12.85M$13.21M$10.59M$7.48M$6.91M$6.35M$10.45M
    R&D$817,000$2.98M$5.26M$4.88M$6.12M$9.68M$10.25M$7.31M$3.71M$3.02M$3.32M$7.23M
    SG&A$3.08M$2.37M$2.71M$2.73M$3.27M$3.17M$2.96M$3.29M$3.77M$3.88M$3.03M$3.22M
    Operating Income$-3,816,000$-5,219,000$-7,792,000$-7,542,000$-9,197,000$-12,770,000$-13,091,000$-10,396,000$-7,380,000$-6,831,000$-6,234,000$-10,318,000
    Interest Income$0$0$0$0$0$0$0$0$0$0$0$0
    Interest Expense$0$0$0$0$0$0$0$0$0$0$0$0
    Income Before Tax$-3,585,000$-4,956,000$-7,426,000$-5,747,000$-8,603,000$-12,010,000$-12,157,000$-9,395,000$-6,241,000$-6,151,000$-6,071,000$-10,038,000
    Income Tax Expense$0$4,000$-146,000$0$0$4,000$0$0$0$0$0$0
    Net Income$-3,585,000$-4,837,000$-7,280,000$-5,755,000$-8,611,000$-12,022,000$-12,157,000$-9,406,000$-6,249,000$-6,188,000$-6,584,000$-10,058,000
    EBITDA$-3,597,000$-4,951,000$-7,420,000$-5,955,000$-8,921,000$-12,554,000$-12,663,000$-10,011,000$-7,018,000$-6,406,000$-6,071,000$-10,038,000
    EBIT$-3,585,000$-4,956,000$-7,426,000$-5,747,000$-8,603,000$-12,010,000$-12,157,000$-9,395,000$-6,241,000$-6,151,000$-6,071,000$-10,038,000
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about VYNE

    News

    Yarrow Bioscience Reports Second Quarter 2026 Financial Results and Provides Business Update

    Yarrow Bioscience announced its second quarter 2026 financial results, highlighting progress in its Phase 2a/2b clinical trial for YB-101, an anti-TSHR antibody for Graves’ disease and thyroid eye disease. The company completed a reverse merger with VYNE Therapeutics and private financings totaling $200 million, securing funding into 2028. Topline results for the Phase 2a portion of the YB-101 trial are expected in the second half of 2027.

    BioSpace•8/13/26•
    Somewhat-Bullish

    Yarrow Bioscience (VYNE) halves losses and completes transformative merger with Yarrow

    Yarrow Bioscience (formerly VYNE Therapeutics) reported a significant reduction in its net loss for the six months ended June 30, 2026, dropping to $6.6 million from $14.4 million a year prior, largely due to decreased R&D spending as legacy programs were wound down. The company completed a strategic merger with privately held Yarrow, changing its name and shifting its focus to clinical-stage development of YB-101 for Graves’ disease and thyroid eye disease. It also conducted a 1-for-50 reverse stock split and declared a special cash dividend as part of the merger process, while noting that Finacea royalty revenues will cease after December 31, 2026.

    Stock Titan•8/13/26•
    Somewhat-Bullish

    Yarrow Bioscience (VYNE): Logos group discloses 10.7% ownership and large warrants

    Logos Global Management LP and associated funds have reported a beneficial ownership of 10.7% in Yarrow Bioscience (VYNE), totaling 286,308 common shares as of July 29, 2026. This group also holds prefunded warrants for an additional 2,201,030 shares, though these are excluded from the reported ownership due to a 9.99% beneficial ownership limitation. The filing emphasizes that these holdings are for investment purposes and not intended to influence control of Yarrow Bioscience.

    Stock Titan•8/7/26•
    Neutral

    Janus Henderson Group (VYNE) reports 9.99% Yarrow Bioscience stake and pre-funded warrants

    Janus Henderson Group Ltd., through its investment adviser subsidiaries, has reported a beneficial ownership of 9.99% in Yarrow Bioscience, Inc. common stock, totaling 266,712 shares held across various managed client accounts. Additionally, the asset managers may beneficially own 1,895,248 pre-funded warrants, which are subject to a 9.99% ownership limitation upon exercise. The firm maintains shared voting and dispositive power over the common shares, with economic benefits accruing to the underlying managed portfolios, including the Janus Henderson Biotech Innovation Master Fund Ltd.

    Stock Titan•8/7/26•
    Neutral

    Vyne Therapeutics Inc (VYNE) Technical Analysis: Support, Resistance, Indicators & Moving Averages

    This article provides a technical analysis of Vyne Therapeutics Inc (VYNE), detailing its current price momentum score, support and resistance levels, and indicator readings. It highlights that VYNE is suitable for range-bound swing trading, with several indicators showing "Buy" signals, particularly its moving averages. The article also includes FAQs explaining technical ratings and moving averages, and offers a summary of current buy/sell signals.

    TradingKey•8/7/26•
    Neutral

    Frequently Asked Questions About VYNE

    Does VYNE pay dividends?
    Vyne Therapeutics Inc (VYNE) has a dividend payment track record. See the VYNE dividend history page for its current payment status, yield, and streaks.
    What is VYNE's market cap?
    Vyne Therapeutics Inc (VYNE) has a market capitalization of $19.07M with a current stock price of $28.56.

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In